The FDA approved Ryaltris nasal spray for treating seasonal allergic rhinitis symptoms in children aged 6 years to less than 12 years, meaning it is now approved for patients aged 6 years and older, according to a press release.The fixed-dose combination Ryaltris (Glenmark Pharmaceuticals) nasal spray was approved for adults and children aged 12 years and older in 2022. It is made up of the

The FDA approved Ryaltris nasal spray for treating seasonal allergic rhinitis symptoms in children aged 6 years to less than 12 years, meaning it is now approved for patients aged…

Nasal spray now approved for seasonal allergic rhinitis in patients aged 6 years and older

Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms…